|Budget Amount *help
¥41,990,000 (Direct Cost: ¥32,300,000、Indirect Cost: ¥9,690,000)
Fiscal Year 2012: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
Fiscal Year 2011: ¥14,560,000 (Direct Cost: ¥11,200,000、Indirect Cost: ¥3,360,000)
Fiscal Year 2010: ¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
This study clarified the distinct pathologic roles of oncogenic β-catenin signaling in colorectal cancer (CRC) from the new biological points of view. They include putative pathologic role for coding region determinant-binding protein (CRD-BP), a novel transcriptional target of β-catenin/Tcfcomplex, in promoting CRC by mediating interaction between Wnt and hedgehog pathways; and the causative relationship among loss of cell polarity, cell adhesion disorder and oncogenic activation of β-catenin in CRC tumorigenesis. We also demonstrated the therapeutic effects of GSK3β inhibition against invasion of gastrointestinal (GI) cancer cells and their resistance to therapies, and uncovered the molecular basis for the novel traetment of GI cancer by targeting GSK3β.